Research programme: adult stem cell-based therapy - wounds - Caladrius Biosciences/Boston University School of Medicine

Drug Profile

Research programme: adult stem cell-based therapy - wounds - Caladrius Biosciences/Boston University School of Medicine

Latest Information Update: 05 Nov 2015

Price : $50

At a glance

  • Originator NeoStem
  • Developer Boston University School of Medicine; Caladrius Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wounds

Most Recent Events

  • 30 May 2014 NeoStem and Boston University School of Medicine agree to co-develop adult stem cell-based wound therapy in USA
  • 26 Mar 2014 Preclinical trials in Wounds (in scleroderma) in USA (unspecified route)
  • 26 Mar 2014 Interim pharmacodynamics data from a preclinical trial in wounds released by NeoStem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top